{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Cancer+to+the+Bone&page=4", "query": { "condition": "Metastatic Cancer to the Bone", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 299, "total_pages": 30, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Cancer+to+the+Bone&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Cancer+to+the+Bone&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T13:59:30.320Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03208712", "title": "Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Radium-223", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2017-11-01", "completion_date": "2018-08-02", "has_results": false, "last_update_posted_date": "2018-10-24", "last_synced_at": "2026-10-11T13:59:30.320Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03208712" }, { "nct_id": "NCT03442556", "title": "Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "ATM Gene Mutation", "BRCA1 Gene Mutation", "BRCA2 Gene Mutation", "Castration Levels of Testosterone", "Castration-Resistant Prostate Carcinoma", "Homologous Recombination Deficiency", "Prostate Carcinoma Metastatic in the Bone", "PSA Level Greater Than or Equal to Two", "PSA Progression", "Stage IV Prostate Adenocarcinoma AJCC v7" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Rucaparib Camsylate", "type": "DRUG" }, { "name": "Rucaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 18, "start_date": "2018-08-24", "completion_date": "2025-06-04", "has_results": true, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-11T13:59:30.320Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03442556" }, { "nct_id": "NCT00544804", "title": "Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Metastatic Cancer" ], "interventions": [ { "name": "lapatinib ditosylate", "type": "DRUG" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "diagnostic laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 41, "start_date": "2007-08", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2014-07-02", "last_synced_at": "2026-10-11T13:59:30.320Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00544804" }, { "nct_id": "NCT00099203", "title": "A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pain", "Bone Neoplasm", "Neoplasm Metastasis" ], "interventions": [ { "name": "ibandronate [Bondronat]", "type": "DRUG" }, { "name": "zoledronic acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 163, "start_date": "2005-07", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2017-08-16", "last_synced_at": "2026-10-11T13:59:30.320Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Sedona, Arizona • Ocoee, Florida + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sedona", "state": "Arizona" }, { "city": "Ocoee", "state": "Florida" }, { "city": "Macon", "state": "Georgia" }, { "city": "Galesburg", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00099203" }, { "nct_id": "NCT00080782", "title": "Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Cancer", "Prostate Cancer" ], "interventions": [ { "name": "Celecoxib", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Strontium chloride Sr 89", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 14, "start_date": "2002-02", "completion_date": "2005-01", "has_results": false, "last_update_posted_date": "2018-10-31", "last_synced_at": "2026-10-11T13:59:30.320Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00080782" }, { "nct_id": "NCT00489203", "title": "Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematopoietic/Lymphoid Cancer", "Accelerated Phase Chronic Myelogenous Leukemia", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Atypical Chronic Myeloid Leukemia", "Blastic Phase Chronic Myelogenous Leukemia", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Chronic Myelogenous Leukemia", "Childhood Myelodysplastic Syndromes", "Chronic Eosinophilic Leukemia", "Chronic Myelomonocytic Leukemia", "Chronic Neutrophilic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "Contiguous Stage II Adult Burkitt Lymphoma", "Contiguous Stage II Adult Diffuse Large Cell Lymphoma", "Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma", "Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma", "Contiguous Stage II Adult Lymphoblastic Lymphoma", "Contiguous Stage II Grade 1 Follicular Lymphoma", "Contiguous Stage II Grade 2 Follicular Lymphoma", "Contiguous Stage II Grade 3 Follicular Lymphoma", "Contiguous Stage II Mantle Cell Lymphoma", "Contiguous Stage II Marginal Zone Lymphoma", "Contiguous Stage II Small Lymphocytic Lymphoma", "de Novo Myelodysplastic Syndromes", "Essential Thrombocythemia", "Extramedullary Plasmacytoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Graft Versus Host Disease", "Isolated Plasmacytoma of Bone", "Juvenile Myelomonocytic Leukemia", "Meningeal Chronic Myelogenous Leukemia", "Myelodysplastic/Myeloproliferative Disease, Unclassifiable", "Nodal Marginal Zone B-cell Lymphoma", "Noncontiguous Stage II Adult Burkitt Lymphoma", "Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma", "Noncontiguous Stage II Adult Lymphoblastic Lymphoma", "Noncontiguous Stage II Grade 1 Follicular Lymphoma", "Noncontiguous Stage II Grade 2 Follicular Lymphoma", "Noncontiguous Stage II Grade 3 Follicular Lymphoma", "Noncontiguous Stage II Mantle Cell Lymphoma", "Noncontiguous Stage II Marginal Zone Lymphoma", "Noncontiguous Stage II Small Lymphocytic Lymphoma", "Previously Treated Myelodysplastic Syndromes", "Primary Myelofibrosis", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Relapsing Chronic Myelogenous Leukemia", "Secondary Myelodysplastic Syndromes", "Stage I Adult Burkitt Lymphoma", "Stage I Adult Diffuse Large Cell Lymphoma", "Stage I Adult Diffuse Mixed Cell Lymphoma", "Stage I Adult Diffuse Small Cleaved Cell Lymphoma", "Stage I Adult Hodgkin Lymphoma", "Stage I Adult Immunoblastic Large Cell Lymphoma", "Stage I Adult Lymphoblastic Lymphoma", "Stage I Adult T-cell Leukemia/Lymphoma", "Stage I Childhood Hodgkin Lymphoma", "Stage I Chronic Lymphocytic Leukemia", "Stage I Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage I Grade 1 Follicular Lymphoma", "Stage I Grade 2 Follicular Lymphoma", "Stage I Grade 3 Follicular Lymphoma", "Stage I Mantle Cell Lymphoma", "Stage I Marginal Zone Lymphoma", "Stage I Multiple Myeloma", "Stage I Mycosis Fungoides/Sezary Syndrome", "Stage I Small Lymphocytic Lymphoma", "Stage II Adult Hodgkin Lymphoma", "Stage II Adult T-cell Leukemia/Lymphoma", "Stage II Chronic Lymphocytic Leukemia", "Stage II Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage II Multiple Myeloma", "Stage II Mycosis Fungoides/Sezary Syndrome", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage III Adult Immunoblastic Large Cell Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Adult T-cell Leukemia/Lymphoma", "Stage III Chronic Lymphocytic Leukemia", "Stage III Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Multiple Myeloma", "Stage III Mycosis Fungoides/Sezary Syndrome", "Stage III Small Lymphocytic Lymphoma", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Adult T-cell Leukemia/Lymphoma", "Stage IV Chronic Lymphocytic Leukemia", "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Mycosis Fungoides/Sezary Syndrome", "Stage IV Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "beclomethasone dipropionate", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 140, "start_date": "2007-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2021-02-03", "last_synced_at": "2026-10-11T13:59:30.320Z", "location_count": 2, "location_summary": "Hackensack, New Jersey • Seattle, Washington", "locations": [ { "city": "Hackensack", "state": "New Jersey" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00489203" }, { "nct_id": "NCT05691478", "title": "A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "High Grade Osteosarcoma", "Localized Osteosarcoma", "Metastatic Osteosarcoma", "Secondary Osteosarcoma" ], "interventions": [ { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Surgical Procedure", "type": "PROCEDURE" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "40 Years", "sex": "ALL", "summary": "Up to 40 Years" }, "enrollment_count": 1122, "start_date": "2023-03-03", "completion_date": "2030-03-20", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-11T13:59:30.320Z", "location_count": 181, "location_summary": "Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 134 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05691478" }, { "nct_id": "NCT01812668", "title": "Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Adenocarcinoma of the Prostate", "Hormone-resistant Prostate Cancer", "Recurrent Prostate Cancer", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "cabozantinib-s-malate", "type": "DRUG" }, { "name": "fluorine F 18 d-FMAU", "type": "RADIATION" }, { "name": "positron emission tomography", "type": "PROCEDURE" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE", "OTHER" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 20, "start_date": "2013-03", "completion_date": "2019-06-18", "has_results": true, "last_update_posted_date": "2021-08-05", "last_synced_at": "2026-10-11T13:59:30.320Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01812668" }, { "nct_id": "NCT00320710", "title": "Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Zoledronic acid", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 416, "start_date": "2006-02", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2014-08-22", "last_synced_at": "2026-10-11T13:59:30.320Z", "location_count": 92, "location_summary": "Anchorage, Alaska • Hot Springs, Arkansas • Springdale, Arkansas + 81 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Campbell", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00320710" }, { "nct_id": "NCT02043678", "title": "Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Radium-223 dichloride (Xofigo, BAY88-8223)", "type": "DRUG" }, { "name": "Matching placebo (normal saline)", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone/Prednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 806, "start_date": "2014-03-30", "completion_date": "2024-02-08", "has_results": true, "last_update_posted_date": "2025-02-19", "last_synced_at": "2026-10-11T13:59:30.320Z", "location_count": 29, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Oceanside, California + 25 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Oceanside", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02043678" } ] }